


Supplementary data:




B


Thymidine kinase modifications		Construct	Name
L 159, I 160, F 161, D R H P I A, A 168, L 169, L C Y P	Wild type TK HSV	Ki67 → TK SH	Ki67-wt-TK
I 159, L 160, A 161, D R H P I A, Y 168, F 169, L C Y P	30 fused with GMK	Ki67 → 30 GMK SH	Ki67-30-GMK
I 159, F 160, L 161, D R H P I A, F 168, M 169, L C Y P	SR39	Ki67 → SR39 SH	Ki67-SR39
Codon optimization for human host cell of the SR39 sequence 218/376 codon changed (Supplementary sequence 1)		Ki67 → SR39h SH	Ki67-SR39h
I 159, F 160, L 161, D R H P I A, F 168, M 169, L C Y P	SR39h + D116E mutation	Ki67 → SR39h D116E SH	Ki67-SR39h D116E

Supplementary Figure S1: Herpes simplex thymidine kinase (TK) variants used in this study.

A) Schematic representation of wild type TK; the two variants generated by Margaret Black (variant 30 and variant SR39) have amino changes close to the highly conserved region (162-164 and 171-173). B) Schematic representation of the different variants. Wild type TK is shown in the top lane, the two Margaret Black variants in lane 2 and 3, and two novel variants created for this study (SR39h and SR39h D116E) are shown in lane 4 and 5. Note that variant 30 was a fusion protein of a TK variant and guanylate kinase (GMK). The humanized SR39h variant codes for the same amino acid sequence as SR39. All variants had an N-terminal “she ble” protein (SH) extension conferring zeocin resistance to cell lines expressing the construct. For most experiments shown in our study, TK variants were expressed under the control of the Ki67 cell-cycle-dependent promoter.




Supplementary Figure S2: Decreased of SR39h and Ki67 protein level during cell differentiation toward neurons. hESC expressing SR39h under the control of the Ki67 promoter were differentiated toward neurons during 42 days. Protein expression of SR39h and the endogenous Ki67 was analyzed by Western blot. The lower panel is a loading control with an anti-actin antibody.



Supplementary Figure S3: Mice weight


Mice were weighed daily during guanosine analogs treatment to identify differences in weight gain/loss between treated groups. No differences were observed between treatment groups.



Supplementary Figure S4: *in vivo* validation of suicide gene. Coronal section of NOD/SCID mice 47 days after injection of hESC expressing the SR39h thymidine kinase variant. Mice were treated for 2x5 days with the respective nucleoside analogs (see Methods). Upper lane: ACV; middle lane: PCV; lower lane: GCV. Sections were colored with cresyl violet and dark purple staining reflects a high density of nuclei. Scale bar 1000 μ m.

HS420 wt 3 weeks

HS420 SR39h 3 weeks



Supplementary Figure S5: *hESC differentiation toward neurons.*

Wild type and SR39h expressing hESC were differentiated towards neurons during 3 weeks. Immunostaining: FOXA2 (mouse, Santa Cruz, sc-374376), beta-III tubulin (β III Tub, mouse, Sigma, T8660), nuclei were counterstained with DAPI.

Supplementary sequence 1: SR39h and SR39 sequence alignment. Viral-TK DNA sequence was humanized using web-based algorithms (www.genscript.com), nucleotides changed in SR39h sequence were labeled in red.

```
>>SR39 1131 bp (1131 nt)
Waterman-Eggert score: 3359; 221.0 bits; E(1) < 3.7e-61
77.5% identity (77.5% similar) in 1129 nt overlap (1-1129:1-1129)

          10      20      30      40      50      60
SR39h  ATGGCCTCTTATCCTGGACACCAGCACGCCAGCGCCTTTGATCAGGCTGCCAGATCTAGA
      :::::  :::::  :::::  :::::  :::::  :::::
SR39   ATGGCTTCGTACCCCGGCCATCAACACGCGTCTGCGTTTCGACCAGGCTGCGCGTTCTCGC
          10      20      30      40      50      60

          70      80      90     100     110     120
SR39h  GGCCACAGCAACAGAAGAACAGCCCTGCGGCCTCGGAGACAGCAAGAGGCTACAGAAGTT
      :::::  :::::  :::::  :::::  :::::  :::::
SR39   GGCCATAGCAACCGACGTACGGCGTTGCGCCCTCGCCGGCAGCAAGAAGCCACGGAAGTC
          70      80      90     100     110     120
```

	130	140	150	160	170	180
SR39h	CGGCCCGAGCAGAAAGATGCCACACTGCTGAGAGTGTACATCGACGGCCCTCACGGCATG					
	:: ::					
SR39	CGCCCCGAGCAGAAAATGCCACGCTACTGCGGGTTTATATAGACGGTCCCCACGGGATG					
	130	140	150	160	170	180
	190	200	210	220	230	240
SR39h	GGCAAGACCACAACAACACAGCTGCTGGTGGCCCTGGGCAGCAGAGATGATATCGTGTAC					
	:: ::					
SR39	GGGAAAACCACCACGCAACTGCTGGTGGCCCTGGGTTTCGCGCGACGATATCGTCTAC					
	190	200	210	220	230	240
	250	260	270	280	290	300
SR39h	GTGCCCGAGCCTATGACCTATTGGAGAGTGTGGGCGCCAGCGAGACAATCGCCAACATC					
	:: ::					
SR39	GTACCCGAGCCGATGACTTACTGGCGGGTGTGGGGGCTTCCGAGACAATCGCGAACATC					
	250	260	270	280	290	300
	310	320	330	340	350	360
SR39h	TACACCACACAGCACCAGCTGGATCAGGGCGAAATTTCCTGCTGGCGACGCCCGCGTGGTT					
	:: ::					
SR39	TACACCACAACAACCCGCTCGACCAGGGTGAGATATCGGCCGGGGACGCGGGCGGTGGTA					
	310	320	330	340	350	360
	370	380	390	400	410	420
SR39h	ATGACATCTGCCCAGATCACCATGGGCATGCCTTACGCCGTGACAGATGCTGTGCTGGCC					
	:: ::					
SR39	ATGACAAGCGCCAGATAACAATGGGCATGCCTTATGCCGTGACCGACGCCGTTCTGGCT					
	370	380	390	400	410	420
	430	440	450	460	470	480
SR39h	CCTCACATTTGGCGGAGAAGCCGGATCTTCTCATGCCCCACCTCCAGCTCTGACCATCTTC					
	:: ::					
SR39	CCTCATATCGGGGGGAGGCTGGGAGCTCACATGCCCCGCCCCGGCCCTCACCATCTTC					
	430	440	450	460	470	480
	490	500	510	520	530	540
SR39h	CTGGACAGACCCCTATCGCCTTCATGCTGTGTTACCCTGCCGCCAGATACCTGATGGGC					
	:: ::					
SR39	CTCGACCGCCATCCCATCGCCTTCATGCTGTGCTACCCGGCCGCGCGGTACCTTATGGGC					
	490	500	510	520	530	540
	550	560	570	580	590	600
SR39h	AGCATGACACCTCAGGCCGTGCTGGCTTTCGTGGCCCTGATTCCCTCCTACACTGCCCGGC					
	:: ::					
SR39	AGCATGACCCCCAGGCCGTGCTGGCGTTTCGTGGCCCTCATCCCGCCGACCTTGCCCGGC					
	550	560	570	580	590	600
	610	620	630	640	650	660
SR39h	ACCAATATCGTGCTGGGAGCCCTGCCCTGAGGACCGGCACATTGATAGACTGGCCAAGAGA					
	:: ::					
SR39	ACCAACATCGTGCTTGGGGCCCTTCCGGAGGACAGACACATCGACCGCTGGCCAACGC					
	610	620	630	640	650	660
	670	680	690	700	710	720
SR39h	CAGCGCCTGGCGAGAGACTGGATCTGGCTATGCTGGCCGCATCAGAAGAGTGTACGGC					

